NCT04639050: Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 241 taking part
- Started
- 15 Mar 2021
- Primary completion
- 31 Jul 2027
- Arms
- Part 1 (Dose Finding) Cohort 1: Dose Level 1 of RO7126209, Part 1 (Dose Finding) Cohort 2: Dose Level 2 of RO7126209, Part 1 (Dose Finding) Cohort 3: Dose Level 3 of RO7126209, Part 1 (Dose Finding) Cohort 4: Dose Level 4 of RO7126209, Part 1 (Dose Finding) Cohort 5: Dose Level 5 of RO7126209, Part 2 (Expansion) Cohort 1: Dose Level 3 of RO7126209, Part 2 (Expansion) Cohort 2: Dose Level 4 of RO7126209, Part 2 (Expansion) Cohort 3: Dose Level 5 of RO7126209, Part 3 (Dose/Frequency/Pharmacodynamic (PD) Relationship): Dose Level 1: RO7126209, Part 3 Dose/Frequency/PD Relationship: Dose Level 2: RO7126209, Part 4: Open Label Extension (OLE)
- Results
- None posted
- 20 Nov 2020: Trial registered
- 15 Mar 2021: Trial started